Tuire Tirkkonen1, Kari Laine. 1. Department of Pharmacology and Clinical Pharmacology, University of Turku, FIN-20520 Turku, Finland. tuire.trikkonen@utu.fi
Abstract
OBJECTIVE: Our objective was to investigate the frequency of potential drug-drug interactions between the prodrugs losartan, codeine, and tramadol and drugs known to inhibit their activation in hospitalized patients. METHODS: The frequency of coadministration between losartan and well-established cytochrome P450 (CYP) 2C9 inhibitors, as well as codeine and tramadol and CYP2D6 inhibitors, was studied by use of data from a university hospital medication database. The study population comprised all patients treated in internal medicine, pulmonary medicine, oncology, and neurology wards (105,533 treatment periods and 65,526 patients) between July 1, 1996, and June 30, 2002 (6 years). RESULTS: Every fifth patient receiving losartan, codeine, or tramadol was concomitantly taking another drug that has the potential to inhibit the activation of these drugs. During the 6-year time period, 1999 patients were exposed to a potential interaction. Interactions occurred more commonly in internal medicine wards (odds ratio, 2.3; 95% confidence interval, 2.1-2.5) and in women (odds ratio, 1.5; 95% confidence interval, 1.4-1.7). CONCLUSIONS: Coadministration of drugs that potentially result in inhibition of prodrug activation present a common and unrecognized source of irrational prescribing.
OBJECTIVE: Our objective was to investigate the frequency of potential drug-drug interactions between the prodrugs losartan, codeine, and tramadol and drugs known to inhibit their activation in hospitalized patients. METHODS: The frequency of coadministration between losartan and well-established cytochrome P450 (CYP) 2C9 inhibitors, as well as codeine and tramadol and CYP2D6 inhibitors, was studied by use of data from a university hospital medication database. The study population comprised all patients treated in internal medicine, pulmonary medicine, oncology, and neurology wards (105,533 treatment periods and 65,526 patients) between July 1, 1996, and June 30, 2002 (6 years). RESULTS: Every fifth patient receiving losartan, codeine, or tramadol was concomitantly taking another drug that has the potential to inhibit the activation of these drugs. During the 6-year time period, 1999 patients were exposed to a potential interaction. Interactions occurred more commonly in internal medicine wards (odds ratio, 2.3; 95% confidence interval, 2.1-2.5) and in women (odds ratio, 1.5; 95% confidence interval, 1.4-1.7). CONCLUSIONS: Coadministration of drugs that potentially result in inhibition of prodrug activation present a common and unrecognized source of irrational prescribing.
Authors: Ylva Böttiger; Kari Laine; Marine L Andersson; Tuomas Korhonen; Björn Molin; Marie-Louise Ovesjö; Tuire Tirkkonen; Anders Rane; Lars L Gustafsson; Birgit Eiermann Journal: Eur J Clin Pharmacol Date: 2009-02-11 Impact factor: 2.953
Authors: Tuukka Saarikoski; Teijo I Saari; Nora M Hagelberg; Janne T Backman; Pertti J Neuvonen; Mika Scheinin; Klaus T Olkkola; Kari Laine Journal: Eur J Clin Pharmacol Date: 2015-01-06 Impact factor: 2.953
Authors: Buster Mannheimer; Björn Wettermark; Michael Lundberg; Hans Pettersson; Christer von Bahr; Erik Eliasson Journal: Br J Clin Pharmacol Date: 2010-04 Impact factor: 4.335
Authors: Nora M Hagelberg; Tuukka Saarikoski; Teijo I Saari; Mikko Neuvonen; Pertti J Neuvonen; Miia Turpeinen; Mika Scheinin; Kari Laine; Klaus T Olkkola Journal: Eur J Clin Pharmacol Date: 2012-10-26 Impact factor: 2.953
Authors: Tuukka Saarikoski; Teijo I Saari; Nora M Hagelberg; Mikko Neuvonen; Pertti J Neuvonen; Mika Scheinin; Klaus T Olkkola; Kari Laine Journal: Eur J Clin Pharmacol Date: 2012-12-15 Impact factor: 2.953
Authors: David C Brousseau; D Gail McCarver; Amy L Drendel; Karthika Divakaran; Julie A Panepinto Journal: J Pediatr Date: 2007-06 Impact factor: 4.406